Results 111 to 120 of about 527 (122)

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology
Background: Aficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in ...
Sheila M Hegde, Michael E Nassif, Ahmad Masri   +2 more
exaly   +2 more sources

Safety and Efficacy of Aficamten in Patients With Non-Obstructive Hypertrophic Cardiomyopathy: A 36-Week Analysis From FOREST-HCM

European Journal of Heart Failure
Aims The aim of this study was to report safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy (nHCM) over 36 weeks in the ongoing FOREST‐HCM trial. Methods and results Patients were started on aficamten 5 mg daily, with doses adjusted in 5‐mg increments (5–20 mg) at ≥2‐week intervals according to site‐read left ...
Albree Tower-Rader, Michael E Nassif, Lisa Meng   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3

Journal of Cardiac Failure, 2023
Albree Tower-Rader, Lisa Meng, Michael A Fifer   +2 more
exaly  

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.

Heart Failure
Albree Tower-Rader, Michael E Nassif, Lisa Meng   +2 more
exaly  

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy

Journal of the American College of Cardiology
Sheila M Hegde, Matthew Lee, Ahmad Masri
exaly  

Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.

Journal of the American College of Cardiology
Michael E Nassif, Maria Luisa, Patricia Réant   +2 more
exaly  

Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

Journal of the American College of Cardiology
Albree Tower-Rader, Michael E Nassif, Pablo Garcia-Pavia   +2 more
exaly  

Pharmacokinetics, Mass Balance, Tissue Distribution, Metabolism, and Excretion of [14C]Aficamten Following Single Oral Dose Administration to Rats

Xenobiotica
Luke Ashcraft, Rajaa Sukhun
exaly  

Echocardiographic Changes With Aficamten: A Pixel Is Worth 1,024 Bits.

Journal of the American College of Cardiology
Milind Y Desai
exaly  

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

New England Journal of Medicine
Sheila M Hegde, Michael E Nassif, Ajith P. Nair   +2 more
exaly